Invesco

Phase A — Understand the business

Lens 1 · Company Overview

Invesco Ltd. is a Bermuda-incorporated, Atlanta-headquartered global asset manager — one operating segment: investment management. It runs $2,169.9B of AUM at 31-Dec-2025, up from $1,846.0B a year earlier. Latest disclosed AUM is $2,257.7B as of 28-Feb-2026 and management cited ~$2.2T average AUM in Q1 2026.

How it makes money. Substantially all revenue is investment-management fees levied as a percentage of AUM. FY2025 operating revenues were $6,377.1M; the bulk is investment-management fees ($4,615.3M) plus service & distribution fees ($1,518.1M). Crucially, net revenue yield (ex-performance fees) fell to 23.0 bps in FY2025 from 25.4 bps in FY2024 and 28.4 bps in FY2023 — the entire business is being repriced downward as assets shift from high-fee active to low-fee passive. Revenue grows because AUM grows faster than yield falls; it is a volume-beats-price machine.

Products / channels. Retail AUM $1,515.7B, Institutional $654.2B. By capability at year-end 2025: ETFs & Index $630.2B (+30% y/y), QQQ $407.2B (+27.7%), Fundamental Fixed Income $311.5B (+11.6%), Fundamental Equities $298.4B (+7.8%), China JV (IGW) $132.5B (+42.2%), Private Markets $130.7B (+0.8%), Global Liquidity $189.7B (−0.9%), Multi-Asset/Other $69.7B (−3.5%). The growth is concentrated in ETFs/Index, QQQ and China; the legacy active complex (Fundamental Equities, Multi-Asset) is flat-to-shrinking on assets and bleeding on flows.

Customers / distribution. Retail distributed through third-party intermediaries — wirehouses, RIA/wealth platforms, regional broker-dealers, banks. No single client is disclosed as a concentration (the customers.csv shelf file is empty; the filing names channels, not named clients) — appropriate for a diversified fund manager. Contracts are terminable on ≤30 days' notice; retail investors can redeem at will — i.e., near-zero contractual lock-in; the only stickiness is performance, brand and platform inertia.

The crypto/tokenization angle (kept in proportion). Invesco sponsors the Invesco Galaxy Bitcoin ETF (BTCO), ~$516M net assets at 11-May-2026 — 0.02% of total AUM. The 10-K explicitly flags tokenization as an emerging opportunity to transform product delivery via "fractionalization and streamlined settlement," and digital-native wealth platforms as a growing flow source. Verdict: optionality, not a driver. Anyone buying IVZ "for crypto" is mis-framing it.

Lens 2 · Supply Chain

Asset management has an inputs→firm→customer chain made of distribution and data, not physical goods:

• Upstream inputs (named):
• Index licensors — the single most important supplier is Nasdaq, Inc., which licenses the Nasdaq-100 Index underlying QQQ ($407B) and the Invesco NASDAQ 100 ETF. This is a genuine single-source dependency: QQQ is ~19% of AUM and its entire economic existence depends on the Nasdaq license.
• Market-data / portfolio vendors — purchase obligations of $1,015.2M at year-end 2025 (up from $694.4M) for "portfolio, market data, office-related services, and third-party marketing" — i.e., Bloomberg/Refinitiv-type feeds and tech.
• Custodians / fund-service providers — sub-transfer agency, call-center and reporting services, reimbursed by the funds.
• The firm: Invesco's investment teams + ~7,499 employees in 20+ countries (down from 8,508 after selling intelliflo + 60% of the India JV).
• Downstream distribution (named chokepoints):
• Wirehouses & wealth platforms — Morgan Stanley, Merrill, UBS, plus RIA custodians (Schwab/Fidelity platforms) gate retail flow. 12b-1 and renewal commissions of $2,127.1M (third-party distribution expense) flow straight back to these distributors — 33% of revenue is passed through to the distribution chain. That is the chain's bargaining power made visible.
• Barings (a MassMutual subsidiary) — new private-markets distribution partner for U.S. wealth (Oct 2025), with MassMutual seeding $650M. Invesco now distributes a product co-managed with its own ~18% shareholder's asset manager.
• Invesco Great Wall (IGW) — 49%-owned China JV, $132.5B AUM, one of China's largest managers; the distribution conduit into China retail.

Chokepoint summary: (1) the Nasdaq-100 license (concentration risk on QQQ); (2) the wirehouse/platform gatekeepers who extract a third of gross revenue; (3) Nasdaq-100 / AI-megacap correlation — the 10-K explicitly warns that a decline in AI-exposed Nasdaq-100 names would hit QQQ AUM and revenue. Invesco's single biggest product is a leveraged bet on the AI megacap complex staying bid.

Lens 3 · Competitive Advantages (moats)

What is the moat? Thin-to-moderate, and narrowing — the honest read for any active-heavy manager.

• Scale (real but not dominant). $2.2T AUM gives operating leverage and the cost base to run global ETFs. But it is dwarfed by BlackRock (~$14T) and Vanguard/State Street in the only durably-growing category — passive — where scale is the moat and Invesco is a distant challenger. QQQ is the exception: a top-5 ETF by AUM with genuine brand.
• QQQ brand / franchise (the one wide-moat asset). The Nasdaq-100 ETF is a household ticker with 25+ years of brand equity and deep liquidity; switching costs for traders (options ecosystem, tax lots) are real. This is the crown jewel and the reason the equity is interesting at all.
• Distribution breadth & diversification. Clients in 120+ countries, balanced across Americas/EMEA/APAC and retail/institutional — genuine diversification that smooths flows. Management calls it a competitive strength; it is more a risk-reducer than a moat.
• Independence. The 10-K argues being a non-bank, non-distributor-conflicted independent is an advantage. Plausible but weak — it didn't stop fee compression.
• Bargaining power: weak on both sides. Against distributors (wirehouses), Invesco pays away 33% of gross revenue — distributors hold the whip. Against clients, contracts terminate on 30 days' notice and fees only fall. The only pricing power is in scarce capabilities (private markets, certain active fixed income), which is precisely where Invesco is sub-scale.

Net: one wide-moat product (QQQ) bolted onto a commoditizing, fee-compressing active book. The moat narrative is "scale + QQQ brand + diversification," and it is real enough to survive but not to compound multiples.

Lens 4 · Segments

Invesco reports one GAAP operating segment, so "segments" = (a) AUM-by-capability and (b) geography.

By capability — flows tell the truth (FY2025 net long-term flows):

Total net long-term flows +$81.2B (≈4.4% organic on beginning AUM) — a genuinely good organic-growth number for a legacy manager, but it nets a strong passive/China engine against a structurally shrinking active-equity book. This split IS the entire thesis tension.

By geography (FY2025 operating revenue): Americas $4,766.1M, EMEA $1,315.7M, APAC $295.3M. EMEA AUM grew +37% and APAC +18.8% y/y vs Americas +13.4% — international is decelerating slower and is the relative growth story. APAC punches below its AUM weight on revenue because the high-AUM China JV is equity-accounted (its revenue sits in "Net revenues," not GAAP operating revenue).

Trend & cause: Accelerating where it's passive/international/China; decelerating-to-shrinking where it's U.S. active equity. Management is explicitly steering capital toward "high-demand, scalable" ETFs + fixed income + private markets.

---

Phase B — Measure performance

Lens 5 · Earnings Result

Two stories: a disastrous GAAP year and a strong underlying year. Reconciling them is the single most important analytical act for this name.

FY2025 (10-K):

• Operating revenues $6,377.1M (+5.1% y/y)
• GAAP operating loss −$695.7M; operating margin −10.9% (vs +13.7% in 2024)
• GAAP net loss −$726.3M; diluted EPS −$1.60 (vs +$1.18)
• Adjusted operating income $1,557.8M; adjusted operating margin 33.4% (up from 31.1%)
• Adjusted net income $922.0M; adjusted diluted EPS $2.03 (up from $1.71, +19%)

The bridge: the GAAP loss is driven entirely by a $1,794.9M non-cash impairment of indefinite-lived intangibles — the management contracts of U.S. retail mutual funds acquired in the 2018 OppenheimerFunds deal. Total amortization & impairment of intangibles was $1,832.4M vs $44.8M in 2024. Strip it out and the underlying business improved: adjusted margin +230 bps, adjusted EPS +19%. The non-cash impairment does not touch liquidity or covenants.

Q1 2026 (10-Q) — a clean acceleration:

• Operating revenues $1,744.5M (+14.1% y/y) — well above the ~$1.27B "consensus" some trackers carried (that consensus excluded the QQQ revenue add)
• GAAP operating income $333.2M; GAAP net income $230.4M; GAAP diluted EPS $0.51 (vs $0.38) — note: GAAP is positive again, the impairment was a one-time 2025 event
• Adjusted operating margin 34.5% (vs 31.5%); adjusted diluted EPS $0.57 (vs $0.44, +30%)
• Net long-term inflows +$21.8B; 11th consecutive quarter of positive organic growth; +$11.5B money-market inflows
• Average AUM $2,218.9B (+18% y/y)

What drove it: the QQQ conversion to an open-end ETF (20-Dec-2025). Under the old unit-investment-trust structure Invesco earned essentially no advisory fee on QQQ; as an open-end fund it now charges an advisory fee on ~$407B of AUM. Investment-management fees jumped to $1,382.2M in Q1 (+$255.3M ex-FX), "driven by new management fees related to QQQ". Third-party distribution costs rose in tandem (+$82.1M) — QQQ is lower-margin than the firm average, hence net revenue yield ticked down to 22.9 bps even as revenue surged. This is a step-change in the revenue base, not organic growth — and it largely repeats for four quarters before lapping.

Balance-sheet flags: cash $1,037.5M; debt rose to $1,825.1M (from $890.6M) to fund the preferred buyback; FY2025 operating cash flow (ex-CIP) $1,360.3M. Healthy cash conversion; the GAAP loss is non-cash.

Market reaction / what's priced in: post-Q1 (late Apr 2026) multiple brokers raised targets (TD Cowen to $32 then $33.50 "best idea for 2026," Goldman $30, JPM $27.50). The stock at ~$29 sits at consensus — the beat was largely absorbed.

Lens 6 · Earnings Calls (sentiment trend)

No transcripts on the research shelf (transcripts/ empty), so this leans on the filings' MD&A tone + web — labeled accordingly.

Tone trajectory (improving, with a structural caveat):

• 2023: defensive — completing the post-Oppenheimer "strategic evaluation" restructuring, $434.8M GAAP operating loss on a prior intangible impairment. Survival-mode language.
• 2024–2025: confident operational momentum — "11 consecutive quarters of positive organic growth," "broad-based flows," margin expansion to >33% adjusted. Schlossberg's recurring framing: "profitable organic growth," "high-demand, scalable capabilities," "act like owners," "strengthen financial flexibility / operating leverage".
• Q1 2026: outright bullish — diversified platform "integral to strong inflows," QQQ modernization landed, Asia ~$700B highlighted.

Recurring phrases (kept): "profitable organic growth," "operating leverage," "diversification," "scalable." Things they stopped saying: the 2023 "strategic evaluation / restructuring" language is gone — the turnaround is declared complete. What's conspicuously soft-pedaled: the secular decline of the U.S. active mutual-fund book, which only surfaces honestly inside the impairment footnote (long-term growth assumption cut to 2.0%, revenue forecast declining 3–9%). The narrative is "diversified growth machine"; the footnotes say "one large legacy leg is dying." Both are true.

Lens 7 · Comps

Peer set: publicly-traded diversified/active asset managers.

Read: IVZ at ~12.8x forward adjusted EPS trades above the cheapest legacy actives (BEN 8.98x, TROW 10.08x) but below the 14.9x industry average — the market awards it a premium-to-the-cheapest for the QQQ/ETF growth tilt, while still discounting it for the active overhang. The standout comp is the data point that isn't a multiple: Janus Henderson — a direct mid-tier active-manager peer — was taken private by Trian + General Catalyst at $52/share (~$7.4B), a healthy premium, approved by 99.7% of shareholders in Apr 2026. That establishes a live private-market clearing price for a sub-scale active manager and makes IVZ (at ~$13B, with a crown-jewel ETF) a credible consolidation candidate or consolidator. Caveat: TROW/BEN/BLK market caps and EV/EBITDA were not cleanly sourced in this pass and are marked n/a rather than guessed.

Lens 8 · Stock-Price Catalysts (last ~5 years — what actually moves IVZ)

Mostly `` + filing-dated events:

• Apr 2020 — dividend cut (slashed the quarterly payout amid COVID + Oppenheimer-integration strain). A credibility scar; the payout has since rebuilt to $0.21/qtr but the 5-yr DPS CAGR is only ~5.9%.
• 2018–2021 — OppenheimerFunds overhang: the $5.7B all-stock acquisition (which created MassMutual's stake) was followed by integration pain, persistent active-equity outflows, and a $254.3M fund-shareholder remediation in Q4 2021. IVZ de-rated to deep value.
• 2020 — MassMutual / Trian dynamics: MassMutual became an ~18% holder via Oppenheimer; Trian (Nelson Peltz) took a stake and pushed for consolidation across the sector. Net: governance/strategic-overhang catalysts.
• 2024–2026 — the re-rate: sustained positive organic growth + margin expansion + the QQQ fee-switch drove the stock from deep-value lows back toward ~$29. Quarterly earnings prints and monthly AUM disclosures (8-Ks) are now the clockwork catalysts — Q1 2026's +14% revenue beat triggered a wave of target hikes.
• Dec 2025 — the QQQ modernization vote + conversion (10% investor fee cut to 0.18%, but new advisory revenue to Invesco) — a structural, one-time positive catalyst.
• Macro / AI beta: because QQQ is ~19% of AUM, IVZ trades partly as a leveraged proxy on the Nasdaq-100 / AI-megacap complex — an AI drawdown is a direct AUM-and-revenue catalyst, flagged in the 10-K's own risk factors.

Pattern: the market reacts to (1) flow inflections, (2) margin/EPS beats, (3) capital-return actions (the preferred buyback, dividend), and (4) the equity-market level via QQQ. It does not pay for the active book — that only ever subtracts.

---

Phase C — Judge people & books

Lens 9 · Management

CEO: Andrew R. Schlossberg (President & CEO and a Director). CFO: L. Allison Dukes.

• Track record: Schlossberg took the CEO seat in mid-2023 and has overseen the operational turnaround now visible in the numbers — adjusted operating margin 28.2% (2023) → 31.1% (2024) → 33.4% (2025) and adjusted EPS $1.51 → $1.71 → $2.03. 11 straight quarters of positive organic growth. That is a real, quantified delivery record on margins and flows.
• Capital-allocation history (the marquee move): in 2025 management repurchased $1.5B of the $4.0B MassMutual Series A Preferred for $1.74B (a $240M / ~16% premium), funding it with term loans + revolver. This deleverages the cap structure of its most expensive capital (5.9% preferred coupon) and is accretive to common over time — a sensible, shareholder-friendly trade, though it added GAAP debt and a one-time $240M premium hit. Modest common buyback ($100.4M, 5.4M shares) and a dividend rebuilt to $0.84/yr.
• Portfolio pruning: sold intelliflo and 60% of the India JV in Q4 2025 (cutting ~1,000 of headcount), and a $71.6M intangible write-off on the disposals — focusing the portfolio. Defensible.
• Skin in the game / tenure: insider ownership not sourced in this pass (insider-transactions.csv absent) — n/a; Schlossberg is a long-tenured Invesco insider (ran the EMEA and US retail businesses before the top job).
• Red flags: (1) the 2020 dividend cut is a credibility mark, albeit COVID-era; (2) the $52.5M regulatory-matters settlement in 2024 plus the $254.3M Oppenheimer remediation in 2021 show a history of compliance/operational stumbles; (3) the CEO is also a Director — the 10-K signature block lists Schlossberg as "President and Chief Executive Officer; Director," and the firm has explicit anti-takeover provisions in its Bye-Laws — governance is not best-in-class.
• Founder vs professional manager: professional manager / career operator. For a mature, scale asset manager mid-transition, that's the right archetype — execution and capital discipline matter more than vision.

Lens 10 · Forensic Red Flags

Acting as a forensic analyst. Invesco's accounting is clean on cash but aggressive in the size of its non-GAAP add-backs — the central quality-of-earnings issue.

• The headline QoE issue — the GAAP/adjusted chasm. FY2025 GAAP net loss −$726.3M vs adjusted net income +$922.0M — a $1,648M swing, the widest possible gap. Most is the legitimate non-cash $1.79B intangible impairment. But the adjustments also strip out a $240M preferred-repurchase premium, $147.6M (2024) comp acceleration, $52.5M (2024) regulatory settlement, $16.9M severance, $8.0M software impairment. Several of these are recurring-in-substance "non-recurring" items (regulatory settlements and restructuring recur across this company's history). Adjusted EPS of $2.03 flatters a messier GAAP reality; haircut it mentally toward ~$1.80–1.90 for "true" run-rate earnings.
• The impairment is a flashing structural signal, not just a write-off. Management cut the long-term growth assumption to 2.0% (from 2.5%) and used a 13.0% discount rate on the U.S. retail mutual-fund contracts, with revenue forecasts declining 3–9% over the forecast horizon. Carrying value of those contracts is now $2,776.8M (down from $4,571.7M) and remains further impairable — a 2% revenue-forecast cut = +$56M more impairment; a 25bps growth cut = +$46M. The company is telling you, in its own model, that a large slice of its book is in managed decline.
• Goodwill: $8,477.1M, tested only qualitatively (no quantitative test run) in 2025. After a $1.8B intangible impairment, a qualitative-only goodwill pass is the more aggressive choice and a watch item if flows deteriorate.
• CIP (Consolidated Investment Products) — presentation noise, not fraud. Invesco consolidates $10,149.8M of CIP assets and $8,967.6M of CIP debt onto its balance sheet that are not available to Invesco and non-recourse. Gross-up inflates total assets ($27.1B GAAP vs $17.4B ex-CIP) and adds volatility to "Other income of CIP." It's standard for the industry and properly disclosed, but it makes the GAAP statements harder to read — always analyze Invesco ex-CIP.
• Cash vs earnings: operating cash flow (ex-CIP) $1,360.3M comfortably exceeds adjusted net income — no negative divergence; receivables/payables move with fee timing. This is the reassuring half: the cash is real.
• SBC: common share-based comp $78.0M in 2025 — modest (~1.2% of revenue); not a meaningful non-GAAP flatterer here (unlike a tech name).

Regulatory findings (required sub-section).

• SEC Litigation Releases / AAERs: none. "No LR found" and "No AAER found" for Invesco in the 2021-06-23→2026-06-23 window via EDGAR EFTS.
• 10-K Item 3 (Legal Proceedings): Invesco points to Note 17, "Commitments and Contingencies." Management states it has been "subject to various regulatory inquiries, reviews and investigations and legal proceedings, including civil litigation, regulatory investigations and enforcement actions" in recent years, but that "adequate accrual has been made… and the ultimate resolution… will not materially affect" the business. Concrete settled matter: the $52.5M regulatory-settlement expense in 2024 (added back in non-GAAP). Historic: the $254.3M OppenheimerFunds shareholder remediation, Q4 2021.
• Non-SEC enforcement (web): no material new FTC/DOJ/CFPB action surfaced for Invesco in this pass; the only named regulatory cash item is the 2024 $52.5M settlement. Note the Bermuda incorporation materially weakens shareholder remedies — class/derivative actions are "generally not available," and the Bye-Laws contain a broad liability waiver for directors/officers absent fraud — a structural investor-protection negative even though it isn't an "enforcement" item.
• Net: No SEC enforcement of record. A pattern of recurring smaller regulatory/operational settlements consistent with a large global manager. Material forensic concerns are accounting-quality (add-back aggressiveness + further-impairable intangibles + qualitative-only goodwill), not fraud.

---

Phase D — Project & stress-test

Lens 11 · Forward Projection (FY2026 / FY2027 / FY2028, adjusted diluted EPS)

Built bottom-up from the Q1 2026 run-rate + the QQQ revenue step-up. Output ``; inputs labeled. Anchor: FY2025 adjusted EPS $2.03; Q1 2026 adjusted EPS $0.57.

Base case — FY2026E adjusted EPS ~$2.45.

• Drivers: full-year QQQ advisory revenue (only ~partial in the FY2025 base since conversion was 20-Dec-2025), ~mid-single-digit organic growth, market beta on AUM, 34–35% adjusted operating margin holding.
• Arithmetic: Q1 $0.57 annualized ≈ $2.28, then add modest sequential growth from AUM appreciation + flow + continued operating leverage, less seasonal Q1-bonus normalization → ~$2.40–2.50. Sense-check: TD Cowen FY2026E $2.58 sits at the top of this band; broad consensus ~$2.40–2.45. My base ~$2.45 is consensus-anchored, a touch below the most bullish broker.

Bull case — FY2026E ~$2.65, FY2027E ~$3.10.

• ETF/QQQ momentum + China JV (+42% AUM) + Barings private-markets ramp + a benign AI-megacap tape lifting QQQ; margin pushes 35–36%. FY2027E ~$3.12 aligns with TD Cowen's published 2027 estimate.

Bear case — FY2026E ~$2.05, FY2027E ~$1.90.

• An equity-market / Nasdaq-100 drawdown cuts QQQ AUM (the leveraged-AI-beta risk), active-equity outflows accelerate (Fundamental Equities already −$21B/yr), net yield compresses below 22 bps, and a further intangible impairment (the book is explicitly still impairable). EPS flat-to-down; multiple de-rates. This is a real path, not a tail.

Three-year sketch (base): FY2026E ~$2.45 → FY2027E ~$2.70 → FY2028E ~$2.90. The QQQ step-up is largely a one-time level-shift that boosts FY2026 then grows with the market.

Per the --watchlist rule, no forecast.ts create was run in this unattended sweep. Suggested tracked forecast for a later human pass: "IVZ FY2026 adjusted diluted EPS ≥ $2.40, p≈0.62, resolves 2027-02-28."

Lens 12 · Bull vs Bear

Bull case. Invesco is a re-rating, cash-generative asset manager whose growth engine (ETFs, QQQ, China, fixed income) is finally outrunning its melting active book, and the market still prices it like a pure legacy active manager (~12.8x fwd adj. EPS vs 14.9x industry). The QQQ open-end conversion is a structural, recurring revenue step-up on $400B+ that the bears underweight. 11 straight quarters of organic growth + 500bps of adjusted-margin expansion since 2023 prove operating leverage is real. The $1.5B preferred buyback cleans up the most expensive capital and is accretive. Capital returns (2.9–3.4% yield + buyback) pay you to wait. And the Janus Henderson take-out at $7.4B / a premium sets a floor-ish private-market value for a sub-scale active manager — IVZ, with a crown-jewel ETF, screens as a consolidation winner either way. Contrarian view the market refuses to see: the QQQ fee-switch quietly converted Invesco's biggest "free" asset into a high-margin annuity, and the AI-beta embedded in QQQ is an upside convexity if the megacap complex keeps compounding.

Bear case (2–3 permanent-impairment risks). (1) Secular active-equity decay is structural, and management just quantified it — a $1.8B impairment, a 2.0% long-term growth assumption, revenue forecast declining 3–9%, and a still-impairable $2.78B carrying value. The high-fee book that funds the margin is in managed decline; growth comes from low-fee product, so net revenue yield falls every single year (28.4→25.4→23.0 bps) and margin expansion is borrowed from mix, not pricing power. (2) QQQ is a leveraged AI-megacap proxy — ~19% of AUM riding the Nasdaq-100; an AI/megacap drawdown hits the single most important product directly (the 10-K says so). (3) The MassMutual overhang — an ~18% holder with two board seats and a now-intertwined Barings product relationship is a permanent governance/strategic constraint, and Bermuda law strips shareholders of class/derivative remedies. Pre-mortem (18 months out, thesis broke): the AI trade rolled over in late 2026, QQQ AUM fell 20%, active-equity outflows re-accelerated, a second intangible impairment hit, and the stock de-rated to ~8–9x like BEN. Are multiples too high? No — they're low, but appropriately so; the discount is the market correctly pricing yield compression + AI-beta + governance, not a mispricing to arbitrage.

Lens 13 · Devil's Advocate (short-seller)

Dismantling the bull case.

• The revenue base is borrowed, not earned. Q1 2026's +14% revenue and the FY2026 EPS bump are dominated by the one-time QQQ structural fee-switch, not durable organic acceleration. Once it laps (Q1 2027), growth reverts to mid-single-digit AUM beta minus relentless yield compression. Bulls are extrapolating a level-shift as a growth rate.
• Where revenue is concentrated, and the shift that breaks it. ~19% of AUM is QQQ — a single index license from Nasdaq tracking the most expensive megacap cohort in market history. If AI-megacap leadership breaks, QQQ AUM and the option-ecosystem stickiness erode together; there is no diversification inside that 19%.
• The moat is weaker than bulls think. Outside QQQ, Invesco competes in commoditizing passive (where BlackRock/Vanguard own scale) and decaying active (where it's losing $21B/yr in equities). Contracts terminate in 30 days; 33% of gross revenue is paid away to distributors who hold the leverage. There is no pricing power.
• Most dangerous competitor bulls underestimate: not BlackRock — it's Vanguard's relentless fee-zeroing in index/ETF, which sets the gravity for QQQ's own fees (already cut to 0.18%). Every basis point Vanguard removes is a ceiling on Invesco's biggest asset.
• Worst capital-allocation / governance items: the 2018 OppenheimerFunds deal is the original sin — it overpaid in stock for a declining active book, created the MassMutual overhang, generated the $254M remediation, and is now the source of $1.8B+ of impairments. Management is still digesting a 2018 mistake. Add the CEO-is-also-Director structure, anti-takeover Bye-Laws, and Bermuda shareholder-remedy stripping.
• Assumptions that must hold for ~$29: equity markets stay elevated (QQQ AUM holds), active-equity outflows stay "only" ~$20B/yr (don't accelerate), no second impairment, and the 34–35% adjusted margin holds despite falling yields. If growth disappoints 20–30% (an AI drawdown taking QQQ down 20% + active outflows doubling), adjusted EPS drops toward ~$1.70–1.90 and a de-rate to BEN-like 8–9x implies a stock in the high-teens — i.e., ~40% downside. The single scenario that permanently impairs: a durable regime shift away from U.S. megacap growth that simultaneously shrinks QQQ and accelerates active-equity redemptions, forcing serial impairments of the Oppenheimer book. Plausibility: moderate — not a tail, given the explicit AI-beta and the already-declining active leg.

Lens 14 · Management Questions (ordered by information value)

1. Now that QQQ is an open-end fund, what is the incremental annual advisory revenue and operating margin on the QQQ franchise specifically, and how should we model it once the conversion laps in Q1 2027?
2. The U.S. retail mutual-fund intangibles were written down to $2,776.8M on a 2.0% long-term-growth assumption and a 3–9% revenue decline — what net flow / market scenario triggers a further impairment, and how much of the remaining carrying value is at risk?
3. Net revenue yield has fallen from 28.4 to 23.0 bps in three years. At what AUM mix does yield stabilize, and can adjusted operating margin hold above 33% if it keeps compressing?
4. Fundamental Equities lost ~$21B in 2025. Is there a floor, or is the plan to let it run off — and at what point does its margin contribution become immaterial?
5. With ~19% of AUM in QQQ tied to the Nasdaq-100, how do you think about concentration risk to the AI-megacap complex, and would you ever diversify the flagship's index exposure?
6. MassMutual owns ~18% of common, $2.5B preferred, two board seats, and is now your Barings private-markets partner. How do you manage the conflicts, and is there a path to fully retiring the preferred?
7. What are the next steps on the preferred stack — do you intend to repurchase the remaining $2.5B, and over what timeframe / funding plan?
8. Given Janus Henderson's take-private at $7.4B, how do you weigh Invesco as a consolidator vs. a consolidation target, and what's the bar for transformative M&A after the Oppenheimer experience?
9. Private Markets is ~$131B but had negative net flows in 2025 despite being a strategic priority. What's wrong with the flow trajectory, and what does the Barings partnership realistically add in 2026–2027?
10. The China JV (IGW) grew AUM +42% to $132.5B. How do you think about the geopolitical / capital-mobility risk to that earnings stream, and what's its true economic contribution net of the noncontrolling interest?
11. Adjusted EPS excludes a recurring cadence of "non-recurring" items (regulatory settlements, restructuring, severance). What is the right normalized run-rate EPS we should anchor to?
12. What is your through-cycle capital-return policy — the split between dividend growth, common buybacks, and preferred retirement — and where does balance-sheet debt cap out (leverage went from 0.25x to 0.73x)?
13. Goodwill of $8.5B was tested qualitatively only. What would force a quantitative goodwill test, and how much cushion is there?
14. Where is AI changing your own cost structure (the 10-K cites "harness innovation including AI") — quantify the opportunity in compensation/G&A operating leverage over three years.
15. On tokenization — beyond the rhetoric, what is the concrete 3-year product roadmap, and is it a revenue opportunity or a defensive cost?

---